

Outpatient Medical Injectable Rituximab and Biosimilars Request Form Fax to 833-581-1861 (Medical Benefit Only)

Member Name:					
Member Date of Birth:					
Member ID (UMI):		☐ Medicare ☐ Commercial			
Ordering/Attending Provider Name:		NPI:			
Ordering/Attending Provider Address:					
Office Contact:	Phone :	#:Fax #:			
Servicing Facility/Vendor Name:		Facility NPI:			
Servicing Facility/Vendor Address:					
Requested Start Date of Service:	equested Start Date of Service: ICD10 Diagnosis Code(s):				
DRUG INFORMATION (please select one	?)				
ONCOLOGY INDICATIONS Ruxience (Q5119) Riabni (Q5123) Rituxan Hycela* (J9311) *Rituxan Hycela policy requires the member to have received at least one full dose of a rituximab product by intravenous infusion	FOR RHEUMATOID ARTHRITIS □ Ruxience (Q5119) □ Riabni (Q5123)	□ Rituxan (J9312) □ Truxima (Q5115) Has the member experienced a documented drug therapy failure or intolerance to the preferred products? Ruxience: □ Yes □ No **A non-preferred product will be considered when the member has a documented drug therapy failure after an adequate therapeutic trial of BOTH preferred products, or BOTH preferred products have not been tolerated or are contraindicated **Medicare members currently established on a non-preferred therapy are not required to try a preferred option.			

^{**}Please verify member's eligibility and benefits through the health plan**

Please answer the following for ONCOLOGY indications: (for non-oncology indications please proceed to question 6)				
1.	What type of cancer does the member have (include histology) and what stage disease?			
2. What is the member's chemotherapy regimen?				
3. What line of therapy is this considered (First, Second, Subsequent)?		apy is this considered (First, Second,		
4. What previous therapies has the member received? (Please include if the member progressed or relapsed)		•		
5.	5. Is the member's disease CD20-positive?		□YES □NO □ NOT APPLICABLE	
Please answer the following for a NON-ONCOLOGY indication: (In addition please make sure the accurate icd10 diagnosis code was given above)				
6. What medications (if any) has the member previously used for this condition?				
7. What medications (if any) will the member be using in conjunction for the condition?		•		
8. What is the dose and frequency of the member's treatment?		and frequency of the member's	Dose: Frequency:	
9.		oid Arthritis indications ONLY S RA moderately to severely active?	□YES □NO	
	New Start	☐ Continu	uation of Therapy	
		Date of last infusion: Has the member demonstrated disease stability or a beneficial response to therapy? YES □ NO		
Please attach all pertinent clinical information				
Attached: YES NO				

This information is issued on behalf of Highmark Blue Shield and its affiliated Blue companies, which are independent licensees of the Blue Cross Blue Shield Association. Highmark Inc. d/b/a Highmark Blue Shield and certain of its affiliated Blue companies serve Blue Shield members in 21 counties in central Pennsylvania and 13 counties in northeastern New York. As a partner in joint operating agreements, Highmark Blue Shield also provides services in conjunction with a separate health plan in southeastern Pennsylvania. Highmark Inc. or certain of its affiliated Blue companies also serve Blue Cross Blue Shield members in 29 counties in western Pennsylvania, 13 counties in northeastern Pennsylvania, the state of West Virginia plus Washington County, Ohio, the state of Delaware, and 8 counties in western New York. All references to Highmark in this document are references to Highmark Inc. d/b/a Highmark Blue Shield and/or to one or more of its affiliated Blue companies